TIV Vaccination Modulates Host Responses to Influenza Virus Infection that Correlate with Protection against Bacterial Superinfection. 2019

Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Angela.Choi@Icahn.mssm.edu.

BACKGROUND Influenza virus infection predisposes to secondary bacterial pneumonia. Currently licensed influenza vaccines aim at the induction of neutralizing antibodies and are less effective if the induction of neutralizing antibodies is low and/or the influenza virus changes its antigenic surface. We investigated the effect of suboptimal vaccination on the outcome of post-influenza bacterial superinfection. METHODS We established a mouse vaccination model that allows control of disease severity after influenza virus infection despite inefficient induction of virus-neutralizing antibody titers by vaccination. We investigated the effect of vaccination on virus-induced host immune responses and on the outcome of superinfection with Staphylococcus aureus. RESULTS Vaccination with trivalent inactivated virus vaccine (TIV) reduced morbidity after influenza A virus infection but did not prevent virus replication completely. Despite the poor induction of influenza-specific antibodies, TIV protected from mortality after bacterial superinfection. Vaccination limited loss of alveolar macrophages and reduced levels of infiltrating pulmonary monocytes after influenza virus infection. Interestingly, TIV vaccination resulted in enhanced levels of eosinophils after influenza virus infection and recruitment of neutrophils in both lungs and mediastinal lymph nodes after bacterial superinfection. CONCLUSIONS These observations highlight the importance of disease modulation by influenza vaccination, even when suboptimal, and suggest that influenza vaccination is still beneficial to protect during bacterial superinfection in the absence of complete virus neutralization.

UI MeSH Term Description Entries

Related Publications

Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
May 2020, Viruses,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
January 2014, Advances in experimental medicine and biology,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
February 2022, Nature medicine,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
November 2023, Vaccine,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
October 2019, Viruses,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
January 2013, PloS one,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
May 2000, Vaccine,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
October 2013, Journal of Korean medical science,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
March 2001, Vaccine,
Angela Choi, and Ioanna Christopoulou, and Xavier Saelens, and Adolfo García-Sastre, and Michael Schotsaert
February 2010, Cell host & microbe,
Copied contents to your clipboard!